Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2022 Filed Mar 9, 2022 02:01 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 2,373 | $12.01 | $28,499.73 |
DisclosureSEC source: 0001209191-22-017401 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,521 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 02:01 UTC |
BENZENO SHARONChief Business Development Off
|
SaleCommon Stock | 2,670 | $12.01 | $32,066.70 |
DisclosureSEC source: 0001209191-22-017398 · doc4.xml · nonDerivative · entry 2 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,596 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 14,815 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-22-017696 · doc4.xml · derivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,185 Underlying: Common Stock · 14,815 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 14,315 | $11.53 | $165,051.95 |
DisclosureSEC source: 0001209191-22-017696 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916,154 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.21 to 12.20, inclusive. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 500 | $12.22 | $6,110.00 |
DisclosureSEC source: 0001209191-22-017696 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,469 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.24, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 14,815 | $6.32 | $93,630.80 |
DisclosureSEC source: 0001209191-22-017696 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:01 UTC |
SOOD NITINChief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 164,745 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017400 · doc4.xml · derivative · entry 2 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,745 Underlying: Common Stock · 164,745 shares Expires 2032-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:01 UTC |
SOOD NITINChief Commercial Officer
|
GrantCommon Stock | 65,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017400 · doc4.xml · nonDerivative · entry 1 SOOD NITIN · CIK 0001877433 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,111 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
PISKEL KYLEPrincipal Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 102,965 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017396 · doc4.xml · derivative · entry 3 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,965 Underlying: Common Stock · 102,965 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
PISKEL KYLEPrincipal Accounting Officer
|
GrantCommon Stock | 41,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017396 · doc4.xml · nonDerivative · entry 1 PISKEL KYLE · CIK 0001780662 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,885 Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC |
ADAMS R MARKChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 185,338 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017392 · doc4.xml · derivative · entry 3 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,338 Underlying: Common Stock · 185,338 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC |
ADAMS R MARKChief Operating Officer
|
GrantCommon Stock | 74,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017392 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,968 Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 154,448 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017397 · doc4.xml · derivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,448 Underlying: Common Stock · 154,448 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
GrantCommon Stock | 61,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017397 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,815 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
GrantCommon Stock | 247,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017393 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920,578 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
LO FRANCISChief People Officer
|
GrantStock Option (Right to Buy) · Derivative | 185,338 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017395 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,338 Underlying: Common Stock · 185,338 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
LO FRANCISChief People Officer
|
GrantCommon Stock | 74,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017395 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,739 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC |
RUBINSTEIN JULIEPresident
|
GrantStock Option (Right to Buy) · Derivative | 463,344 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017399 · doc4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,344 Underlying: Common Stock · 463,344 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC |
RUBINSTEIN JULIEPresident
|
GrantCommon Stock | 185,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017399 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,126 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 617,792 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017394 · doc4.xml · derivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,792 Underlying: Common Stock · 617,792 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
GrantCommon Stock | 247,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017394 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,477 Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC |
BENZENO SHARONChief Business Development Off
|
GrantStock Option (Right to Buy) · Derivative | 205,931 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017398 · doc4.xml · derivative · entry 3 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,931 Underlying: Common Stock · 205,931 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC |
BENZENO SHARONChief Business Development Off
|
GrantCommon Stock | 82,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017398 · doc4.xml · nonDerivative · entry 1 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,266 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
OWEN KATEY EINTERZDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005494 · doc4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
OWEN KATEY EINTERZDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005494 · doc4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,132 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Pellini Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005499 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Pellini Michael JDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005499 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Conroy Kevin TDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005498 · doc4.xml · derivative · entry 2 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Conroy Kevin TDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005498 · doc4.xml · nonDerivative · entry 1 Conroy Kevin T · CIK 0001306119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005497 · doc4.xml · derivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005497 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
HERSHBERG ROBERTDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005496 · doc4.xml · derivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
HERSHBERG ROBERTDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005496 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
NEUPERT PETER MDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005495 · doc4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
NEUPERT PETER MDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005495 · doc4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,193 Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Trigg LeslieDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,722 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-22-005493 · doc4.xml · derivative · entry 2 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,722 Underlying: Common Stock · 16,722 shares Expires 2032-01-26 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| January 26, 2022 Filed Jan 29, 2022 00:00 UTC |
Trigg LeslieDirector
|
GrantCommon Stock | 6,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005493 · doc4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,132 Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 20:00 UTC |
ADAMS R MARKChief Operating Officer
|
SaleCommon Stock | 1,021 | $23.32 | $23,809.72 |
DisclosureSEC source: 0001209191-22-002766 · doc4.xml · nonDerivative · entry 1 ADAMS R MARK · CIK 0001808905 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,833 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,208 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-071194 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,709 Underlying: Common Stock · 5,208 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,130 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-071194 · doc4.xml · derivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,313 Underlying: Common Stock · 10,130 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 15,338 | $30.00 | $460,140.00 |
DisclosureSEC source: 0001209191-21-071194 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 5,208 | $7.80 | $40,622.40 |
DisclosureSEC source: 0001209191-21-071194 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 10,130 | $6.55 | $66,351.50 |
DisclosureSEC source: 0001209191-21-071194 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. Read SEC document |
| December 22, 2021 Filed Dec 24, 2021 02:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001209191-21-071193 · doc4.xml · derivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2021 Filed Dec 24, 2021 02:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-21-071193 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| December 22, 2021 Filed Dec 24, 2021 02:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $7.27 | $72,700.00 |
DisclosureSEC source: 0001209191-21-071193 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · derivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,800 Underlying: Common Stock · 300 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 300 | $31.36 | $9,408.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.00 to 31.76, inclusive. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 300 | $6.55 | $1,965.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 21:59 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-065839 · doc4.xml · derivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,100 Underlying: Common Stock · 3,700 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.